Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

To evaluate the clinical relevance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) measured by a recently developed enzyme-linked immunosorbent assay (ELISA), we analysed both components in samples derived from 892 patients with primary breast cancer (median follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales: de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362263/
https://www.ncbi.nlm.nih.gov/pubmed/10098758
http://dx.doi.org/10.1038/sj.bjc.6690191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362263/
https://www.ncbi.nlm.nih.gov/pubmed/10098758
http://dx.doi.org/10.1038/sj.bjc.6690191

Ejemplares similares